Christopher Tacke, Krasimira Aleksandrova, Miriam Rehfeldt, Veronica Murahovschi, Mariya Markova, Margrit Kemper, Silke Hornemann, Ulrike Kaiser, Caroline Honig, Christiana Gerbracht, Stefan Kabisch, Tina Hörbelt, D Margriet Ouwens, Martin O Weickert, Heiner Boeing, Andreas F H Pfeiffer, Olga Pivovarova, Natalia Rudovich
WNT1 inducible signaling pathway protein 1 (WISP-1/CCN4) is a novel adipokine, which is upregulated in obesity, and induces a pro-inflammatory response in macrophages in-vitro. Preclinical observations suggested WISP-1/CCN4 as a potential candidate for novel obesity therapy targeting adipose tissue inflammation. Whether circulating levels of WISP-1/CCN4 in humans are altered in obesity and/or type 2 diabetes (T2DM) and in the postprandial state, however, is unknown. This study assessed circulating WISP-1/CCN4 levels in a) paired liquid meal tests and hyperinsulinemic- euglycemic clamps (cohort I, n = 26), b) healthy individuals (cohort II, n = 207) and c) individuals with different stages of obesity and glucose tolerance (cohort III, n = 253)...
September 2018: Journal of Cell Communication and Signaling